Results 201 to 210 of about 8,209 (210)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis

Dermatologic Therapy, 2022
, Dingding Zhang
exaly  

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

New England Journal of Medicine, 2021
Marina Magrey, Joseph F Merola, Kishimoto Mitsumasa   +2 more
exaly  

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

Gastroenterology, 2020
Subrata Ghosh, Julian Panes, Tanida S
exaly  

Upadacitinib

Reactions Weekly, 2022
openaire   +2 more sources

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet, The, 2018
Mark C Genovese, Roy M Fleischmann, Bernard Combe   +2 more
exaly  

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2018
Gerd R Burmester, Joel M Kremer, Filip E Van Den Bosch   +2 more
exaly  

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Lancet, The, 2019
Désirée M Van Der Heijde, Atul Deodhar, Mrcp, Filip E Van Den Bosch   +2 more
exaly  

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

New England Journal of Medicine, 2020
Jeffrey Enejosa, Boulos Haraoui, Maureen Rischmueller   +2 more
exaly  

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

New England Journal of Medicine, 2023
exaly  

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Annals of the Rheumatic Diseases, 2019
Roy M Fleischmann, Mark C Genovese, Eduardo Mysler   +2 more
exaly